Conflict of interest The authors have no conflict of interest to

Conflict of interest The authors have no conflict of interest to declare and warrant that the results presented in this paper have not been published previously in whole or part, except in abstract format. References 1. Vaziri ND, Norris K. Lipid disorders and their relevance

to outcomes in chronic kidney Seliciclib clinical trial disease. Blood Purif. 2011;31(1–3):189–96.PubMedCrossRef 2. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am J Physiol Renal Physiol. 2006;290:262–72.CrossRef 3. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993;21:573–92.PubMed 4. Vaziri ND. Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial. 2009;22(6):644–51.PubMedCrossRef 5. Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010;6(5):287–96.PubMedCrossRef 6. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int. 1992;41:1653–61.PubMedCrossRef 7. Catrran DC, Fenton SS, Wilson DR, Steiner G. Defective

triglyceride removal in learn more lipemia associated with peritoneal dialysis and haemodialysis. Ann Intern Med. 1976;85:29–33. 8. Horkko S, Huttunen K, Korhonen T, Kesaniemi YA. Decreased clearance of low-density lipoprotein in patients with chronic renal failure. Kidney Int. 1994;45:561–70.PubMedCrossRef 9. Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S, selleck screening library Blum M, Peer G, Laina A. Severe defect in clearing postprandial chylomicron remnants in dialysis patients. Kidney Int. 1992;42:1247–52.PubMedCrossRef 10. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG. Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest. 1996;97:2167–73.PubMedCrossRef 11. Vaziri ND, Liang K. Down regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int. 1997;51:913–9.PubMedCrossRef 12. Kim C, Vaziri ND. Downregulation of hepatic LDL receptor-related protein (LRP) in chronic

renal failure. Kidney Int. 2005;67:1028–32.PubMedCrossRef 13. Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely affects lipid metabolism ADAMTS5 in chronic renal failure. Kidney Int. 1990;37:854–8.PubMedCrossRef 14. Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50:1928–35.PubMedCrossRef 15. Vaziri ND, Wang XQ, Liang K. Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol (Renal Physiol). 1997;273(42):F925–30. 16. Sendak RA, Bensadoun A. Identification of a heparin-binding domain in the distal carboxyl-terminal region of lipoprotein lipase by site-directed mutagenesis. J Lipid Res. 1998;39:1310–5.PubMed 17.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>